Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ITRM |
---|---|---|
09:32 ET | 253 | 1.44 |
09:36 ET | 2400 | 1.4316 |
09:38 ET | 200 | 1.45 |
09:48 ET | 4181 | 1.4351 |
09:52 ET | 100 | 1.4465 |
09:54 ET | 500 | 1.4436 |
09:59 ET | 778 | 1.44 |
10:01 ET | 666 | 1.45 |
10:24 ET | 100 | 1.44 |
10:26 ET | 134 | 1.4322 |
10:44 ET | 100 | 1.4489 |
10:53 ET | 133 | 1.44 |
11:04 ET | 300 | 1.44 |
11:06 ET | 500 | 1.44 |
11:08 ET | 150 | 1.44 |
11:20 ET | 600 | 1.4316 |
11:26 ET | 6011 | 1.4301 |
11:36 ET | 498 | 1.4317 |
12:20 ET | 1155 | 1.45 |
12:25 ET | 100 | 1.44 |
12:32 ET | 668 | 1.4492 |
12:48 ET | 250 | 1.4301 |
12:50 ET | 3445 | 1.44 |
12:52 ET | 7718 | 1.45 |
12:59 ET | 3260 | 1.45 |
01:01 ET | 400 | 1.445 |
01:10 ET | 100 | 1.44 |
01:30 ET | 1600 | 1.4463 |
01:51 ET | 4952 | 1.4499 |
02:15 ET | 980 | 1.4466 |
02:18 ET | 1200 | 1.45 |
02:20 ET | 1800 | 1.44 |
02:27 ET | 2200 | 1.445 |
02:45 ET | 3327 | 1.4432 |
02:49 ET | 300 | 1.45 |
03:09 ET | 200 | 1.46 |
03:23 ET | 200 | 1.44 |
03:34 ET | 497 | 1.4301 |
03:48 ET | 568 | 1.46 |
03:50 ET | 200 | 1.46 |
03:54 ET | 120 | 1.4599 |
03:57 ET | 300 | 1.4301 |
03:59 ET | 436 | 1.43 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Iterum Therapeutics PLC | 23.5M | -0.5x | --- |
Lisata Therapeutics Inc | 23.7M | -1.1x | --- |
Cardio Diagnostics Holdings Inc | 23.5M | -1.5x | --- |
Bullfrog AI Holdings, Inc. | 23.7M | -3.3x | --- |
CERo Therapeutics Holdings Inc | 22.7M | -4.1x | --- |
Context Therapeutics Inc | 22.5M | -0.9x | --- |
Iterum Therapeutics plc is a clinical-stage pharmaceutical company. The Company develops differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. It is advancing its first compound, sulopenem, a novel penem anti-infective compound, in Phase 3 clinical development with an oral formulation. Sulopenem is a potent, thiopenem antibiotic delivered intravenously, which is active against bacteria that belong to the group of organisms known as gram-negatives and causes urinary tract and intra-abdominal infections. It has also developed sulopenem in an oral tablet formulation, sulopenem etzadroxil-probenecid. Sulopenem also has an IV formulation. Sulopenem has demonstrated potent in vitro activity against a variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $23.5M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 16.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.34 |
EPS | $-2.96 |
Book Value | $-0.47 |
P/E Ratio | -0.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.